ArQule Gross Profit 2006-2019 | ARQL

ArQule gross profit from 2006 to 2019. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
ArQule Annual Gross Profit
(Millions of US $)
2018 $26
2017 $
2016 $5
2015 $11
2014 $11
2013 $16
2012 $36
2011 $47
2010 $29
2009 $25
2008 $14
2007 $9
2006 $7
2005 $7
ArQule Quarterly Gross Profit
(Millions of US $)
Q2 2019 $0
Q1 2019 $1
Q4 2018 $3
Q3 2018 $5
Q2 2018 $14
Q1 2018 $4
Q4 2017
Q3 2017
Q2 2017
Q1 2017
Q4 2016 $1
Q3 2016 $1
Q2 2016 $1
Q1 2016 $1
Q4 2015 $3
Q3 2015 $3
Q2 2015 $3
Q1 2015 $3
Q4 2014 $3
Q3 2014 $3
Q2 2014 $3
Q1 2014 $3
Q4 2013 $2
Q3 2013 $4
Q2 2013 $4
Q1 2013 $6
Q4 2012 $5
Q3 2012 $11
Q2 2012 $12
Q1 2012 $8
Q4 2011 $17
Q3 2011 $12
Q2 2011 $5
Q1 2011 $13
Q4 2010 $8
Q3 2010 $8
Q2 2010 $7
Q1 2010 $6
Q4 2009 $7
Q3 2009 $6
Q2 2009 $6
Q1 2009 $5
Q4 2008 $5
Q3 2008 $3
Q2 2008 $3
Q1 2008 $4
Q4 2007 $3
Q3 2007 $3
Q2 2007 $2
Q1 2007 $2
Q4 2006 $2
Q3 2006 $2
Q2 2006 $2
Q1 2006 $2
Q4 2005 $2
Q3 2005 $2
Q2 2005 $6
Q1 2005 $7
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $1.147B $0.026B
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $60.478B 37.25
Astellas Pharma (ALPMY) Japan $26.786B 13.13
Takeda Pharmaceutical (TAK) Japan $25.935B 8.10
Grifols, S.A (GRFS) Spain $15.044B 19.19
UCB SA (UCBJF) Belgium $15.008B 0.00
Eisai (ESALY) Japan $14.613B 25.12
Merck (MKGAF) Germany $13.590B 18.55
Ionis Pharmaceuticals (IONS) United States $9.533B 20.56
Ono Pharmaceutical (OPHLF) Japan $9.383B 20.06
Neurocrine Biosciences (NBIX) United States $8.905B 0.00
Sage Therapeutics (SAGE) United States $8.736B 0.00
IPSEN SA ADR (IPSEY) France $8.634B 0.00
Catalent (CTLT) United States $8.049B 32.30
Jazz Pharmaceuticals (JAZZ) Ireland $7.407B 9.75
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.257B 19.83
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.101B 0.00
STADA ARZNEIMI (STDAF) Germany $5.547B 0.00
Orion OYJ (ORINY) Finland $5.275B 27.16
Hypermarcas (HYPMY) Brazil $4.969B 17.86
FibroGen (FGEN) United States $3.783B 94.63
United Therapeutics (UTHR) United States $3.633B 0.00
Evotec AG (EVTCY) Germany $3.240B 44.36
Taro Pharmaceutical Industries (TARO) Israel $3.101B 11.11
Arrowhead Pharmaceuticals (ARWR) United States $3.045B 69.83
Nektar Therapeutics (NKTR) United States $2.976B 0.00
Tilray (TLRY) Canada $2.833B 0.00
PTC Therapeutics (PTCT) United States $2.663B 0.00
Xencor (XNCR) United States $2.196B 47.89
Zogenix (ZGNX) United States $2.189B 0.00
Portola Pharmaceuticals (PTLA) United States $1.968B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.580B 57.49
CLINIGEN GP (CLIGF) United Kingdom $1.577B 0.00
USANA Health Sciences (USNA) United States $1.477B 14.81
Corcept Therapeutics (CORT) United States $1.451B 19.94
Heron Therapeutics (HRTX) United States $1.443B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.392B 22.97
Ironwood Pharmaceuticals (IRWD) United States $1.387B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.200B 0.00
Aerie Pharmaceuticals (AERI) United States $1.101B 0.00
Radius Health (RDUS) United States $1.101B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.916B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.802B 3.57
TherapeuticsMD (TXMD) United States $0.675B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.640B 0.00
Endo (ENDP) Ireland $0.636B 1.12
Karyopharm Therapeutics (KPTI) United States $0.567B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.538B 0.00
Indivior (INVVY) United States $0.537B 1.94
Akebia Therapeutics (AKBA) United States $0.506B 0.00
Dermira (DERM) United States $0.488B 0.00
Concordia (CXRXF) Canada $0.476B 0.00
Aptorum Group (APM) China $0.469B 0.00
Dova Pharmaceuticals (DOVA) United States $0.436B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.429B 0.00
Translate Bio (TBIO) United States $0.429B 0.00
Organogenesis Holdings (ORGO) United States $0.426B 0.00
Flexion Therapeutics (FLXN) United States $0.423B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.422B 19.20
Siga Technologies (SIGA) United States $0.409B 0.96
ChemoCentryx (CCXI) United States $0.403B 0.00
Collegium Pharmaceutical (COLL) United States $0.395B 0.00
ImmunoGen (IMGN) United States $0.388B 0.00
CV Sciences (CVSI) United States $0.378B 0.00
Innate Pharma SA (IPHYF) France $0.374B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.362B 0.00
Harpoon Therapeutics (HARP) United States $0.325B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.318B 0.00
Xeris Pharmaceuticals (XERS) United States $0.309B 0.00
DURECT (DRRX) United States $0.294B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.284B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.277B 0.00
KalVista Pharmaceuticals (KALV) United States $0.277B 0.00
Recro Pharma (REPH) United States $0.277B 0.00
CannTrust Holdings (CTST) Canada $0.273B 0.00
Lannett Co Inc (LCI) United States $0.270B 2.62
OptiNose (OPTN) United States $0.262B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.239B 0.00
Concert Pharmaceuticals (CNCE) United States $0.238B 0.00
Ardelyx (ARDX) United States $0.226B 0.00
Ocular Therapeutix (OCUL) United States $0.221B 0.00
Calithera Biosciences (CALA) United States $0.207B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.197B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.179B 0.00
Molecular Templates (MTEM) United States $0.177B 0.00
Nature's Sunshine Products (NATR) United States $0.175B 29.19
Taiwan Liposome (TLC) Taiwan $0.174B 0.00
Redhill Biopharma (RDHL) Israel $0.159B 0.00
GlycoMimetics (GLYC) United States $0.146B 0.00
IMV INC (IMV) Canada $0.142B 0.00
Generex Biotechnology (GNBT) United States $0.136B 0.00
Majesco Entertainment (PTE) United States $0.127B 0.00
Jounce Therapeutics (JNCE) United States $0.127B 0.00
MEI Pharma (MEIP) United States $0.118B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.117B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.112B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.109B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Aquestive Therapeutics (AQST) United States $0.101B 0.00
Cardiome Pharma (CORV) Canada $0.101B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.099B 0.00
Neos Therapeutics (NEOS) United States $0.095B 0.00
Mast Therapeutics (SVRA) United States $0.094B 0.00
Iterum Therapeutics (ITRM) Ireland $0.090B 0.00
Nivalis Therapeutics (ALPN) United States $0.086B 0.00
MediWound (MDWD) Israel $0.085B 0.00
Genocea Biosciences (GNCA) United States $0.085B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.083B 31.59
Avadel Pharmaceuticals (AVDL) Ireland $0.081B 0.00
RENEURON GP (RNUGF) United Kingdom $0.080B 0.00
Natural Alternatives (NAII) United States $0.075B 7.48
China SXT Pharmaceuticals (SXTC) China $0.071B 0.00
Otonomy (OTIC) United States $0.071B 0.00
Champions Oncology (CSBR) United States $0.069B 591.00
Lipocine (LPCN) United States $0.068B 0.00
Infinity Pharmaceuticals (INFI) United States $0.067B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.065B 0.00
Novan (NOVN) United States $0.064B 0.00
SCYNEXIS (SCYX) United States $0.064B 0.00
Pharmaxis (PXSLY) Australia $0.060B 0.00
Capnia (SLNO) United States $0.060B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.059B 0.00
ElectroCore (ECOR) United States $0.052B 0.00
Medicure (MCUJF) Canada $0.052B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.052B 0.00
Aclaris Therapeutics (ACRS) United States $0.045B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.045B 0.00
Forward Pharma (FWP) Denmark $0.044B 0.00
CTI BioPharma (CTIC) United States $0.042B 0.00
Mannatechorporated (MTEX) United States $0.039B 0.00
Bio-Path Holdings (BPTH) United States $0.035B 0.00
Melinta Therapeutics (MLNT) United States $0.035B 0.00
PharmAthene (ALT) United States $0.033B 0.00
Biomerica (BMRA) United States $0.028B 0.00
ProPhase Labs (PRPH) United States $0.024B 0.00
Opexa Therapeutics (ACER) United States $0.023B 0.00
Heat Biologics (HTBX) United States $0.019B 0.00
HANCOCK JAFFE (HJLI) United States $0.019B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.018B 1.41
Achieve Life Sciences (ACHV) United States $0.016B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.015B 0.00
Cyanotech (CYAN) United States $0.015B 0.00
Shineco (TYHT) China $0.014B 0.00
Onconova Therapeutics (ONTX) United States $0.013B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.012B 0.00
Regulus Therapeutics (RGLS) United States $0.012B 0.00
VAXART, INC (VXRT) United States $0.011B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.010B 0.00
RXi Pharmaceuticals (PHIO) United States $0.008B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.008B 0.00
Xenetic Biosciences (XBIO) United States $0.007B 0.00
Flex Pharma (SLRX) United States $0.006B 0.00
Jaguar Animal Health (JAGX) United States $0.006B 0.00
Midatech Pharma (MTP) United Kingdom $0.004B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.003B 0.00
Advanced Accelerator Applications S.A (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00